These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 7884433)

  • 1. Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial.
    Veldhuis GJ; Willemse PH; van Gameren MM; Aalders JG; Mulder NH; Mull B; Biesma B; de Vries EG
    J Clin Oncol; 1995 Mar; 13(3):733-40. PubMed ID: 7884433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma.
    Hofstra LS; Kristensen GB; Willemse PH; Vindevoghel A; Meden H; Lahousen M; Oberling F; Sorbe B; Crump M; Sklenar I; Sluiter WJ; Kiese B; Trope CG; de Vries EG
    J Clin Oncol; 1998 Oct; 16(10):3335-44. PubMed ID: 9779710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of interleukin-3 after chemotherapy for advanced ovarian cancer.
    Biesma B; Willemse PH; Mulder NH; Sleijfer DT; Gietema JA; Mull R; Limburg PC; Bouma J; Vellenga E; de Vries EG
    Blood; 1992 Sep; 80(5):1141-8. PubMed ID: 1515636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
    Rinehart J; Margolin KA; Triozzi P; Hersh E; Campion M; Resta D; Levitt D
    Clin Cancer Res; 1995 Oct; 1(10):1139-44. PubMed ID: 9815905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
    Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
    Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study.
    Postmus PE; Gietema JA; Damsma O; Biesma B; Limburg PC; Vellenga E; de Vries EG
    J Clin Oncol; 1992 Jul; 10(7):1131-40. PubMed ID: 1318953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficiency, safety and tolerability of recombinant human interleukin-3 (rhIL-3) as supportive therapy accompanying dose-intensive carboplatin containing chemotherapy in ovarian cancer with special regard to thrombocytopenia].
    Meden H; Fock M; Krauss T; Kuhn W
    Zentralbl Gynakol; 1999; 121(8):375-83. PubMed ID: 10486880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. SDZ ILE 964 (IL-3) Study.
    Kudoh S; Sawa T; Kurihara N; Furuse K; Kurita Y; Fukuoka M; Takada M; Takaku F; Ogawa M; Ariyoshi Y
    Cancer Chemother Pharmacol; 1996; 38 Suppl():S89-95. PubMed ID: 8765425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer.
    Veldhuis GJ; Willemse PH; Sleijfer DT; van der Graaf WT; Groen HJ; Limburg PC; Mulder NH; de Vries EG
    J Clin Oncol; 1995 Oct; 13(10):2585-93. PubMed ID: 7595711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer.
    Runowicz CD; Mandeli J; Speyer JL; Wadler S; Hochster H; Garrison L; Holland JF
    Am J Obstet Gynecol; 1996 Apr; 174(4):1151-9; discussion 1159-60. PubMed ID: 8623842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study.
    D'Hondt V; Weynants P; Humblet Y; Guillaume T; Canon JL; Beauduin M; Duprez P; Longueville J; Müll R; Chatelain C
    J Clin Oncol; 1993 Nov; 11(11):2063-71. PubMed ID: 8229120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human interleukin-3 administered concomitantly with chemotherapy in patients with relapsed small cell lung cancer.
    Biesma B; van Kralingen KW; van Leen RW; Koster MC; Postmus PE
    J Exp Ther Oncol; 2002; 2(1):47-52. PubMed ID: 12415620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of recombinant human interleukin-3 on haematological recovery from chemotherapy-induced myelosuppression.
    Tepler I; Elias A; Kalish L; Shulman L; Strauss G; Skarin A; Lynch T; Levitt D; Resta D; Demetri G
    Br J Haematol; 1994 Aug; 87(4):678-86. PubMed ID: 7986706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of cyclosphosphamide and carboplatinum combined with interleukin-3 in women with advanced-stage ovarian cancer.
    Speyer JL; Mandeli J; Hochster H; Runowicz C; Wadler S; Wallach R; Cohen C; Oette D; Sorich J; Demakos E
    Gynecol Oncol; 1995 Mar; 56(3):387-94. PubMed ID: 7705673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin.
    Isaacs C; Robert NJ; Bailey FA; Schuster MW; Overmoyer B; Graham M; Cai B; Beach KJ; Loewy JW; Kaye JA
    J Clin Oncol; 1997 Nov; 15(11):3368-77. PubMed ID: 9363868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II trial of cyclophosphamide, mitoxantrone, and escalated doses of carboplatin supported by peripheral-blood stem cells in women with metastatic breast cancer.
    Patnaik A; MacKinnon J; Goss P; Nagy T; Stewart K; Keating A; Crump M
    J Clin Oncol; 2000 Jun; 18(12):2363-8. PubMed ID: 10856095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer.
    Vadhan-Raj S; Kudelka AP; Garrison L; Gano J; Edwards CL; Freedman RS; Kavanagh JJ
    J Clin Oncol; 1994 Apr; 12(4):707-14. PubMed ID: 8151314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
    Tepler I; Cannistra SA; Frei E; Gonin R; Anderson KC; Demetri G; Niloff J; Goodman H; Muntz H; Muto M
    J Clin Oncol; 1993 Aug; 11(8):1583-91. PubMed ID: 8101563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.